

SQSTM1 Antibody

Catalog # ASC11000

Product Information

Application	WB, IF, E, IHC-P
Primary Accession	Q13501
Other Accession	Q13501 , 74735628
Reactivity	Human, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	IgG
Calculated MW	47687
Concentration (mg/ml)	1 mg/mL
Conjugate	Unconjugated
Application Notes	SQSTM1 antibody can be used for detection of SQSTM1 by Western blot at 1 - 2 μ g/mL. Antibody can also be used for immunohistochemistry starting at 5 μ g/mL. For immunofluorescence start at 20 μ g/mL.

Additional Information

Gene ID	8878
Other Names	Sequestosome-1, EBI3-associated protein of 60 kDa, EBIAP, p60, Phosphotyrosine-independent ligand for the Lck SH2 domain of 62 kDa, Ubiquitin-binding protein p62, SQSTM1, ORCA, OSIL
Target/Specificity	SQSTM1;
Reconstitution & Storage	SQSTM1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Precautions	SQSTM1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	SQSTM1 {ECO:0000303 PubMed:16286508, ECO:0000312 HGNC:HGNC:11280}
Function	Molecular adapter required for selective macroautophagy (aggrephagy) by acting as a bridge between polyubiquitinated proteins and autophagosomes (PubMed: 15340068 , PubMed: 15953362 , PubMed: 16286508 , PubMed: 17580304 , PubMed: 20168092 , PubMed: 22017874 , PubMed: 22622177 , PubMed: 24128730 , PubMed: 28404643 , PubMed: 29343546 , PubMed: 29507397 , PubMed: 31857589 , PubMed: 33509017 , PubMed: 34471133 , PubMed: 34893540 ,

PubMed:[35831301](#), PubMed:[37306101](#), PubMed:[37802024](#)). Promotes the recruitment of ubiquitinated cargo proteins to autophagosomes via multiple domains that bridge proteins and organelles in different steps (PubMed:[16286508](#), PubMed:[20168092](#), PubMed:[22622177](#), PubMed:[24128730](#), PubMed:[28404643](#), PubMed:[29343546](#), PubMed:[29507397](#), PubMed:[34893540](#), PubMed:[37802024](#)). SQSTM1 first mediates the assembly and removal of ubiquitinated proteins by undergoing liquid-liquid phase separation upon binding to ubiquitinated proteins via its UBA domain, leading to the formation of insoluble cytoplasmic inclusions, known as p62 bodies (PubMed:[15911346](#), PubMed:[20168092](#), PubMed:[22017874](#), PubMed:[24128730](#), PubMed:[29343546](#), PubMed:[29507397](#), PubMed:[31857589](#), PubMed:[37802024](#)). SQSTM1 then interacts with ATG8 family proteins on autophagosomes via its LIR motif, leading to p62 body recruitment to autophagosomes, followed by autophagic clearance of ubiquitinated proteins (PubMed:[16286508](#), PubMed:[17580304](#), PubMed:[20168092](#), PubMed:[22622177](#), PubMed:[24128730](#), PubMed:[28404643](#), PubMed:[37802024](#)). SQSTM1 is itself degraded along with its ubiquitinated cargos (PubMed:[16286508](#), PubMed:[17580304](#), PubMed:[37802024](#)). Also required to recruit ubiquitinated proteins to PML bodies in the nucleus (PubMed:[20168092](#)). Also involved in autophagy of peroxisomes (pexophagy) in response to reactive oxygen species (ROS) by acting as a bridge between ubiquitinated PEX5 receptor and autophagosomes (PubMed:[26344566](#)). Acts as an activator of the NFE2L2/NRF2 pathway via interaction with KEAP1: interaction inactivates the BCR(KEAP1) complex by sequestering the complex in inclusion bodies, promoting nuclear accumulation of NFE2L2/NRF2 and subsequent expression of cytoprotective genes (PubMed:[20452972](#), PubMed:[28380357](#), PubMed:[33393215](#), PubMed:[37306101](#)). Promotes relocalization of 'Lys-63'-linked ubiquitinated STING1 to autophagosomes (PubMed:[29496741](#)). Involved in endosome organization by retaining vesicles in the perinuclear cloud: following ubiquitination by RNF26, attracts specific vesicle-associated adapters, forming a molecular bridge that restrains cognate vesicles in the perinuclear region and organizes the endosomal pathway for efficient cargo transport (PubMed:[27368102](#), PubMed:[33472082](#)). Sequesters tensin TNS2 into cytoplasmic puncta, promoting TNS2 ubiquitination and proteasomal degradation (PubMed:[25101860](#)). May regulate the activation of NFKB1 by TNF-alpha, nerve growth factor (NGF) and interleukin-1 (PubMed:[10356400](#), PubMed:[10747026](#), PubMed:[11244088](#), PubMed:[12471037](#), PubMed:[16079148](#), PubMed:[19931284](#)). May play a role in titin/TTN downstream signaling in muscle cells (PubMed:[15802564](#)). Adapter that mediates the interaction between TRAF6 and CYLD (By similarity).

Cellular Location

Cytoplasmic vesicle, autophagosome. Preautophagosomal structure. Cytoplasm, cytosol. Nucleus, PML body. Late endosome. Lysosome. Nucleus Endoplasmic reticulum. Cytoplasm, myofibril, sarcomere {ECO:0000250|UniProtKB:O08623}. Note=In cardiac muscle, localizes to the sarcomeric band (By similarity). Localizes to cytoplasmic membraneless inclusion bodies, known as p62 bodies, containing polyubiquitinated protein aggregates (PubMed:[11786419](#), PubMed:[20357094](#), PubMed:[22017874](#), PubMed:[29343546](#), PubMed:[29507397](#), PubMed:[31857589](#), PubMed:[37306101](#), PubMed:[37802024](#)). In neurodegenerative diseases, detected in Lewy bodies in Parkinson disease, neurofibrillary tangles in Alzheimer disease, and HTT aggregates in Huntington disease (PubMed:[15158159](#)). In protein aggregate diseases of the liver, found in large amounts in Mallory bodies of alcoholic and nonalcoholic steatohepatitis, hyaline bodies in hepatocellular carcinoma, and in SERPINA1 aggregates (PubMed:[11981755](#)) Enriched in Rosenthal fibers of pilocytic astrocytoma (PubMed:[11786419](#)). In the cytoplasm, observed in both membrane-free ubiquitin-containing protein aggregates (sequestosomes) and membrane-surrounded autophagosomes (PubMed:[15953362](#), PubMed:[17580304](#)).

Colocalizes with TRIM13 in the perinuclear endoplasmic reticulum (PubMed:22178386). Co-localizes with TRIM5 in cytoplasmic bodies (PubMed:20357094). When nuclear export is blocked by treatment with leptomycin B, accumulates in PML bodies (PubMed:20168092) {ECO:0000250|UniProtKB:O08623, ECO:0000269|PubMed:11786419, ECO:0000269|PubMed:11981755, ECO:0000269|PubMed:15158159, ECO:0000269|PubMed:15953362, ECO:0000269|PubMed:17580304, ECO:0000269|PubMed:20168092, ECO:0000269|PubMed:20357094, ECO:0000269|PubMed:22017874, ECO:0000269|PubMed:22178386, ECO:0000269|PubMed:29343546, ECO:0000269|PubMed:29507397, ECO:0000269|PubMed:31857589, ECO:0000269|PubMed:37306101, ECO:0000269|PubMed:37802024}

Tissue Location Ubiquitously expressed.


Background

SQSTM1 Antibody: SQSTM1/p62 is an adapter protein which binds ubiquitin and regulates signaling cascades through ubiquitination. It may regulate the activation of NF- κ B by TNF- α , nerve growth factor (NGF) and interleukin-1. SQSTM1/p62, a co-interacting protein of the atypical PKC isoforms, has a UBA domain at its C-terminal end, which binds non-covalently to polyubiquitin chain. SQSTM1's UBA domain is necessary for recruitment of polyubiquitin and aggresome formation. SQSTM1 may play a role in titin/TTN downstream signaling in muscle cells and may be involved in cell differentiation, apoptosis, immune response and regulation of K⁺ channels. Mutations in the ubiquitin-associated (UBA) domain of SQSTM1 commonly cause Paget's disease of bone since the UBA is necessary for aggregate sequestration and cell survival.

References



Seibenhener ML, Babu JR, Geeth T, et al. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. *Mol. Cell. Biol.*2004; 24:8055-68.
Hocking LJ, Lucas GJ, Daroszewska A, et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. *Hum. Mol. Genet.*2002; 11:2735-9.
Rousiere M, Michou L, Cornelis F, et al. Paget's disease of bone. *Best Pract. Res. Clin. Rheumatol.*2003; 17:1019-41.
Layfield R, Ciani B, Ralston SH, et al. Structural and functional studies of mutations affecting the UBA domain of SQSTM1 (p62) which cause Paget's disease of bone. *Biochem. Soc. Trans.*2004; 32:728-30.

Images



Western blot analysis of SQSTM1 in Human spleen tissue lysate with SQSTM1 antibody at (A) 1 and (B) 2 µg/mL.

Immunohistochemistry of SQSTM1 in rat spleen tissue with SQSTM1 antibody at 5 µg/mL.



Immunofluorescence of SQSTM1 in Rat Spleen cells with SQSTM1 antibody at 20 $\mu\text{g/mL}$.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.